- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology.
Times cited: 99